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Background: After acute necrotizing pancreatitis (ANP), a pancreatic fistula may occur from discon-
nected pancreatic duct syndrome (DPDS) where a segment of the pancreas is no longer in continuity with
the main pancreatic duct.
Aim: To study the outcome of patients treated using Roux-Y pancreatic fistula tract-jejunostomy for
DPDS after ANP.
Methods: Between 2002 and 2011, patients treated for DPDS in the setting of endoscopic retrograde
cholangiopancreatography (ERCP) or magnetic resonance cholangiopanreatography (MRCP) docu-
mented main pancreatic duct disruption with Roux-Y pancreatic fistula tract-jejunostomy.
Results: In all, seven patients with DPDS were treated. The median age was 62 years (range 49–78) and
five were men. The cause of ANP was gallstones (2), alcohol (1), ERCP (1) and idiopathic (3). Pancreatic
necrosectomy was done in six patients. Time from onset of pancreatitis to fistula drainage was 270 days
(164–365). Pancreatic fistulae arose from DPDS in the head/neck (4) and body/tail (3). Patients had a
median fistula output of 140 ml (100–200) per day before surgery. The median operative time was 142 min
(75–367) and estimated blood loss was 150 ml (25 to 500). Patients began an oral diet on post-operative
day 4 (3–6) and were hospitalized for a median of 7 days (5–12). The median follow-up was 264 days
(29–740). Subsequently, one patient required a distal pancreatectomy. After surgery, three patients
required oral hypoglycaemics. No patient developed pancreatic exocrine insufficiency.
Conclusion: Internal surgical drainage using Roux-en-Y pancreatic fistula tract-jejunostomy is a safe
and definitive treatment for patients with DPDS.
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Introduction
Acute pancreatitis is an inflammatory disorder of the pancreas
that is mild and self-limiting in 80% of patients whereas severe
and associated with complications in the remaining 20% of
patients.1 In its most severe form, necrosis of the pancreas occurs
with loss of viable pancreatic parenchyma and pancreatic ductal
elements. Disconnected left-sided pancreatic duct syndrome
(DPDS) is a recognized complication of severe acute necrotizing
pancreatitis (ANP) characterized by disruption of the main pan-
creatic duct with a loss of continuity between the pancreatic duct
and the gastrointestinal tract.2 It has been defined as identification
of main pancreatic duct cut-off or an inability to access the
upstream pancreatic duct using endoscopic retrograde cholangio-
pancreatography (ERCP), disruption of the duct on magnetic
resonance cholangiopanreatography (MRCP) and/or contrast-
enhanced computed tomography (CT) evidence of viable pancre-
atic tissues upstream from a discontinuous pancreas and/or
pancreatic duct.
Portions of this work were presented at the 9th World Congress of the
International Hepato-Pancreato-Biliary Association 18 to 22 April 2010 in
Buenos Aires, Argentina.
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The clinical manifestations of DPDS include a persistent non-
healing pancreatic fistula after debridement and/or drainage of
pancreatic necrosis or pancreatic pseudocyst formation.2 In the
patient with a non-healing pancreatic pseudocyst, treatment
options include endoscopic drainage, internal surgical drainage or
external percutaneous drainage. Patients who have external per-
cutaneous drainage or surgical debridement after ANP may
develop a pancreatic fistula.3 While most fistulae heal with time
reflecting preserved continuity of the main pancreatic duct, a
fistula associated with DPDS may fail to heal.4 The volume of
fistula output is a function of the amount of viable pancreas
downstream from the pancreatic duct disruption. Patients with
DPDS have an increased risk of diabetes mellitus, metabolic and
nutritional derangements from chronic loss of protein and
electrolyte-rich pancreatic fluid, portal hypertension and chronic
disability.4,5
Treatment options include observation, endoscopic stent place-
ment to bridge the disrupted duct and surgical therapy.2,4,5 Surgi-
cal options include a distal pancreatectomy to remove the viable
pancreas downstream of the ductal disruption and internal sur-
gical drainage of the pancreatic fistula. The main disadvantages of
resection include loss of viable pancreas which may worsen an
already compromised pancreatic endocrine and exocrine function
and the technical difficulties andmorbidity of attempted resection
in the setting of prior severe pancreatitis. This present study is a
review of the clinical outcomes of a strategy of Roux-en-Y internal
drainage of a pancreatic fistula after debridement and drainage of
patients for complications of necrotizing pancreatitis
Methods
Between 2002 and 2011, a retrospective chart review from a ter-
tiary care centre was performed on patients treated with Roux-
en-Y drainage of a persistent pancreatic fistula for DPDS after
ANP, identified from our hospital database. Medical records were
reviewed for patient demographics, aetiology of necrotizing pan-
creatitis, imaging [CT, magnetic resonance imaging (MRI) and
ERCP] and laboratory findings, treatment (internal surgical
drainage), clinical course and outcomes (length of stay, time to
diet, endocrine and exocrine insufficiency, pathology and mor-
bidity). DPDS was defined as previously described by the Inter-
national Symposium on Acute Pancreatitis (Atlanta, GA, USA)
and as outlined in a previous study by Tann et al.2,6 All patients
received a pre-operative CT scan of the abdomen and DPDS was
confirmed with ERCP or MRCP.7 A persistent pancreatic fistula
was defined as any measurable volume of fluid on or after post-
operative day 3 with an amylase level greater than three times
the normal limit of serum amylase activity.8 Surgery was indi-
cated in patients who failed conservative medical management,
endoscopic intervention or experienced 3 months or more of
persistent fistula drainage of more than 100 ml per day. Three
surgeons at a single academic institution performed internal
drainage of a persistent pancreatic fistula with Roux-en-Y pan-
creatic fistula tract-jejunostomy using an open technique. The
technique utilized is illustrated in Fig. 1. Briefly, patients were
explored via a midline laparotomy. The internal portion of the
previously placed drain was identified with surrounding fibrous
tissue tract. The fibrous tract containing the surgical drain was
dissected down to its insertion onto the surface of the pancreas
or base of the transverse mesocolon, if applicable. The drain is
removed and the fistula tract is divided. A 40-cm Roux limb is
anastomozed to the fistula tract with an interrupted 4-0
monofilament absorbable suture. Successful surgical outcome
was defined as resolution of fluid collections and internal drain-
age of a persistent pancreatic fistula.
Results
Seven patients with DPDS were identified (five men and two
women) with a median age of 61 years (range 49–78). Necrotiz-
ing pancreatitis was caused by cholelithiasis,2 idiopathic,3 alco-
hol1 and ERCP.1 At the time of diagnosis and treatment of the
necrotizing pancreatitis, pancreatic drainage or debridement
procedures were performed in all patients: open pancreatic
necrosectomy,6 percutaneous drainage1 and endoscopic drain-
age.1 The time from onset of pancreatitis to internal drainage of
the pancreatic fistula was a median of 270 days (range 164–365)
and median fistula output before internal drainage was 140 ml/
day (range 100–200).
Contrast-enhanced CT showed evidence of a loss of pancreatic
parenchyma consistent with segmental pancreatic necrosis in all
patients (Fig. 2a and 2b). MRCP was utilized in four patients
demonstrating discontinuity of the main pancreatic duct and iso-
lation of a viable distal pancreas (Fig. 3). The disconnection
within the pancreatic duct was identified in the head/neck region
or in the body/tail of the pancreas in four and three patients,
respectively.
All patients underwent an open Roux-Y pancreatic fistula tract-
jejunostomy for DPDS, details noted in Table 1. Two patients had
internal drainage as a solitary procedure whereas five patients had
internal drainage combined with other procedures including a
cholecystectomy,3 cyst-gastrostomy for pseudocysts remote from
the fistula tract and main duct disruption2 and small bowel resec-
tion.1 All patients had drains placed in the vicinity of the fistula
tract anastomosis. Patients were followed up in the clinic for a
median of 264 days (range 29–740).
Overall, initial internalization of the pancreatic fistula was suc-
cessful with Roux-Y pancreatic fistula tract-jejunostomy in all7
patients. Subsequently, one patient required a distal pancreatec-
tomy and splenectomy as a consequence of delayed hemorrhage
of a splenic artery pseudoaneurysm associated with a new
pseudocyst in the splenic hilum remote from the site of fistula
tract drainage. Long-term follow-up imaging (6 to 12months) has
been performed in five of the patients showing no recurrence of
pancreatic fluid collections (Fig. 2c). No ductal dilation or distal
gland atrophy was observed in any of these patients. Procedure-
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specific morbidity included wound infection,2 transient anasto-
motic leak managed with continuation of post-surgical drain
placement until resolution,2 incisional hernia,2 percutaneous aspi-
ration of post-operative sterile fluid collection1 and infectious
colitis.1 The post-operative fluid collection had normal fluid
amylase and, therefore, did not represent an anastomotic leak.
Pancreas-specific morbidity occurred in one patient with a recur-
rent pseudocyst associated with a ruptured splenic artery
pseudoaneurysm that could not be managed with endovascular
techniques and required surgical control. No patients developed
recurrent pancreatitis. All patients had preservation of pancreatic
exocrine function in that none had post-operative symptoms of
exocrine insufficiency nor did any require pancreatic enzyme
supplementation. With regard to endocrine function, three
patients required oral hypoglycaemic agents post-operatively for
continuation of pancreatic endocrine insufficiency present after
necrosectomy and preceding fistula tract internal drainage. No
patients required insulin therapy.
Discussion
Disconnected pancreatic duct syndrome as a complication of
necrotizing pancreatitis is characterized by main pancreatic duct
discontinuity between viable pancreas and the gastrointestinal
tract and is increasingly recognized in the literature.2,4–6,9,10 The
presence of a non-healing pancreatic fistula is most commonly
attributed to the development of pancreatic parenchymal necrosis
as a result of severe acute pancreatitis.11
Each of the patients in the current series had debridement of
pancreatic and peri-pancreatic necrosis for complications of
necrotizing pancreatitis. At the time of the initial surgery, debri-
dement was approached by a laparotomy with opening into the
lesser sac for debridement either directly through the gastrocolic
omentum or through windows made in the base of the trans-
verse mesocolon. The later was the preferred approach as the
gastrocolic-omental plane is most often fused and inaccessible
whereas the transverse mesocolon protects the greater sac from
Figure 1 Roux-en-Y pancreatic fistula tract-jejunosomy for disconnected pancreatic duct syndrome. (a) Dissection of a pancreatic fistula
associated with an external pancreatic drainage catheter left through the root of the transverse mesocolon at the time of the initial pancreatic
necrosectomy. (b) Opening of a fistula tract and the placement of stay sutures. (c) Construction of Roux-en-Y pancreatic fistula tract
jejunosomy. (d) Completed anastomosis
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the inflammatory process, offering a relatively easy window into
the lesser sac. At the time of the initial necrosectomy, surgical
drains were placed into the lesser sac to overlie the debrided
pancreatic parenchymal edge and brought through the transverse
mesocolon window to the skin. In all patients, debridement was
accomplished with one operation and a 10-mm closed suction
drain. This ensured drainage of pancreatic fluid in the case of
ductal disruption. For most patients, drainage catheters can be
removed with cessation of pancreatic fluid drainage indicating
healing of pancreatic ductal disruption. Each drain was protected
from the surrounding small and large intestine by a tongue of
omentum to prevent enteric erosion of the drain and facilitate
robust fistula tract formation surrounding the surgical drain in
the case of a non-healing pancreatic fistula. In these patients,
Roux-en-Y drainage was performed. The Roux-en-Y anastomosis
was placed as low on the fistula tract as possible, usually flush with
the pancreas through the transverse mesocolon. A direct pancre-
atic duct to jejunal mucosa was not typically achieved, instead a
Figure 2 Contrast-enhanced computed tomography of discon-
nected pancreatic duct treatment. (a) Surgical drain sitting in the
pancreatic bed corresponding to the region of the pancreatic neck
and body after debridement of these areas during pancreatic necro-
sectomy (arrow) The pancreatic fistula arises from viable pancreas
anatomically to the left of the disrupted duct. (b) One-year follow-up
computed tomography (CT) post internal drainage by Roux-en-Y
fistula tract jejunostomy (arrow)
Figure 3 Magnetic resonance cholangiopancreatography (MRCP) of
disconnected pancreatic duct syndrome. Disconnected pancreatic
duct between viable pancreas A and ampulla B. The arrow denotes
area of missing pancreatic duct
Table 1 Outcomes
Outcome measure Median Range
General
Operative time (min) 142 75–367
Blood loss (ml) 150 25–500
Start of the diet (days) 4 3–6
Hospital stay (days) 7 5–12
Post-operative drain
removal (days)
10 5–30
Pancreas specific
Exocrine insufficiency None
Endocrine insufficiency
Oral hypoglycaemic
agents
3
Insulin None
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jejunal anastomosis to the fistula tract itself proved effective. This
strategy provided a reliable, safe and technically simple approach
to internal drainage.
Surgical management of a persistent pancreatic fistula dates
back to 1937 when Lahey published the first report of a success-
ful pancreaticojejunostomy.12 Currently, there are two surgical
options available for the treatment of DPDS:1 internal drainage
with a Roux-en-Y panctreaticoenterostomy and2 resection of the
viable pancreatic segment by distal pancreatectomy. The patients
in this series most commonly had disruption of the pancreatic
duct in the head/neck region of the pancreas; a matter that has
been previously recognized in the literature.2 For this reason,
resection of the pancreas downstream of the ductal disruption
could entail resection of a large volume of otherwise viable pan-
creas with resultant further loss of pancreatic function. Other
series in the literature have advocated the safety and success of
internal drainage by Roux-en-Y pancreaticojejunostomy when
compared with distal pancreatectomy.9,13,14 These series include
patients with fistulae arising from several aetiologies including
pancreatitis, trauma and post-surgical fistulae whereas the
current series focuses entirely on patients with fistulae arising
from necrotizing pancreatitis. In 2001, Howard et al. presented
findings of successful Roux-en-Y internal drainage in 13
patients: nine using pancreaticojejunostomy and four using cys-
tojejunostomy.9 Patients with pancreatic pseudocysts as a mani-
festation of their DPDS were excluded from the current series.
When compared with distal pancreatectomy, Howard et al.
reported that internal drainage was a shorter operation
technically less demanding and resulted in less blood loss than
distal resection. They commented that distal pancreatectomy
is technically demanding in this situation due to the tedious
dissection and tissue inflammation and support the observation
that internal drainage conserves functioning pancreatic tissue
and facilitates preservation of the spleen.
Findings by Bassi of 17 patients with external pancreatic fis-
tulas resistant to medical therapy were surgically corrected by
fistulojejunostomy.13 Only four patients suffered morbidity after
surgery with successful internal drainage in all patients. Bassi
recommends surgery within 1.5–3 months after onset of a pan-
creatic fistula, whereas other authors recommend waiting 6
months or 1 year until surgical correction as spontaneous
closure of a pancreatic fistula has been demonstrated up to a
year after the acute episode.14,15 An additional advantage of
delayed treatment is optimization of patient nutritional and
functional status after their critical illness associated with the
initial necrotizing pancreatitis and development of a robust
fistula tract surrounding the surgical drain allowing for a more
robust target for Roux-en-Y drainage. Unlike pancreatic
pseudocysts, there are no data available to guide surgeons to the
optimal time necessary for maturation of the fistula tract to a
point where sutures will securely hold. In the current cohort,
internal drainage was performed a median of 9 months after the
diagnosis of a pancreatic fistula.
Endoscopic therapy may be diagnostic as well as therapeutic for
drainage of a pancreatic fistula in DPDS. In 1991, Kozarek treated
14 patients with DPDS using transpapillary drainage with seven
patients ultimately requiring surgery as a result of ongoing pain or
recurrent fluid collection.16 In 2002, Telford treated 43 patients for
pancreatic duct disruption with transpapillary stent placement
and found a 75% failure rate in patients with DPDS becaues of
acute pancreatitis.17 A subsequent series of 189 patients with a
pancreatic fluid collection or fistula identified 30 patients with
DPDS located at the pancreatic tail; surgical therapy was eventu-
ally required in 63% of patients.5 At this point, the authors believe
surgical therapy is successful as an initial and definitive approach;
more data is needed to determine the future of endoscopic inter-
vention for this complex disease.
External pancreatic fistulas in the setting of acute necrotizing
pancreatitis with DPDS are safely and definitively managed by
Roux-en-Y pancreatic fistula tract-jejunostomy. This procedure is
easy to perform, preserves pancreatic exocrine and endocrine
function and is associated with an acceptable level of morbidity.
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